pubrio
Specialised Therapeutics Asia

Specialised Therapeutics Asia

Singapore · Pharmaceuticals

Pharmaceuticals

Specialised Therapeutics is an international, independent pharmaceutical company providing specialist medicines to patients in Australia, New Zealand and across South East Asia. Founded in 2008 by international pharmaceutical executives Carlo Montagner and Bozena Zembrzuski, Specialised Therapeutics began with a single oncology product that is now one of the most successful branded chemotherapies ever commercialised in Australia. Since its inception, the ST product portfolio has expanded, now spanning oncology, haematology, neurology, supportive care, genomic assays and ophthalmology - although it is not confined to these therapy areas. ST is headquartered in Singapore, with representative offices in Australia and New Zealand. It partners with international biotech and pharmaceutical companies, expertly championing their products from pre-registration to full commercialisation in key AU, NZ and SE Asia regions. With extensive experience navigating complex regulatory and reimbursement pathways in diverse markets, it maintains a highly successful track record of commercialising specialty products. International Partners include: . Incyte Biosciences International . Celgene (acquired by BMS) . Puma Biotechnology . Helsinn Healthcare . photonamic GmbH . Ariad Pharmaceuticals (now Takeda Pharmaceuticals) . Genomic Health Inc (now Exact Sciences) . Alimera Sciences Inc . PharmaMar . Onconova Therapeutics

Company Insights
Company Overview

2007

Founded

Pharmaceuticals

Industry

Singapore

Location

8,133,941

Ranking

40 employees

Size

Similar Companies

Get full access to view complete information

Frequently Asked Questions Regarding Specialised Therapeutics Asia

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​